Related by context. All words. (Click for frequent words.) 82 ALN PCS 76 ALN TTR# 76 transthyretin TTR mediated amyloidosis 75 transthyretin mediated amyloidosis ATTR 75 ALN HPN 75 ALN VSP 74 CYT# potent vascular disrupting 74 Solazed TM 74 PNP inhibitor 74 CCX# 74 oral prodrug 73 CEQ# 73 JAK2 inhibitor 73 RNAi Therapeutic 73 RNAi therapeutic targeting 72 MEK inhibitor 72 orally administered inhibitor 72 tiapamil 72 systemic RNAi therapeutic 72 novel VDA molecule 72 Panzem R 71 histone deacetylase HDAC inhibitor 71 FOLOTYN ® 71 Traficet EN 71 Hepatitis C Virus HCV 71 CD# CEA 71 antagomirs 71 Azedra 71 XL# XL# 71 HCV protease inhibitor 71 rxRNA 71 Phase 2b Clinical Trial 70 Tezampanel 70 synthetic retinoid 70 targeted radiotherapeutic 70 Personalized Immunotherapy 70 XL# anticancer compounds 70 HCV polymerase 70 oral proteasome inhibitor 70 Squalamine 70 Omacetaxine 70 forodesine 70 familial amyloidotic polyneuropathy FAP 70 PEG SN# 70 R#/MEM # 70 Familial Adenomatous Polyposis FAP 70 dasatinib Sprycel ® 70 Zemiva TM 70 CORT # 70 AAG geldanamycin analog 70 Archexin 70 delivered RNAi therapeutic 70 targeting PCSK9 69 Spiegelmer ® 69 cMET 69 refractory chronic lymphocytic 69 TKB# 69 Phase #b/#a clinical 69 NS5A 69 fosbretabulin 69 Liposomal 69 OMNARIS HFA 69 JAK2 Inhibitor 69 myelofibrosis polycythemia vera 69 AEG# 69 tanespimycin 69 investigational humanized monoclonal antibody 69 Onalta ™ 69 IAP inhibitors 69 Novel Oral 69 selective androgen receptor modulator 69 VitiGam 69 HuLuc# 69 targeting CD# 69 virus HCV protease inhibitor 69 LNP formulations 69 MKC# MT 69 proteasome inhibitor 69 alvespimycin 69 essential thrombocythemia ET 69 protein kinase inhibitor 69 peripherally acting 69 Presents Preclinical Data 69 novel histone deacetylase 69 kidney urologic 69 Zenvia ™ 69 Alfacell proprietary ribonuclease 69 oncolytic virus therapies 69 Meets Primary Endpoint 69 PDE4 inhibitor 69 IAP inhibitor 69 HQK 69 Initiate Clinical Trial 68 metaglidasen 68 First Patient Dosed 68 TRANSDUR ™ 68 non alcoholic steatohepatitis 68 non nucleoside inhibitor 68 JAK1 68 selective modulator 68 protein tyrosine phosphatase 1B 68 IL# PE#QQR 68 systemically administered 68 Dapagliflozin 68 candidate CRLX# 68 Chemophase 68 humanized anti 68 Completes Patient Enrollment 68 lexidronam injection 68 anticancer compound 68 receptor tyrosine kinase inhibitor 68 antibody MAb 68 Safinamide 68 MAGE A3 ASCI 68 modified glutathione analog 68 lintuzumab SGN 68 CR# vcMMAE 68 MT#/MEDI-# 68 HCV polymerase inhibitors 68 Phase 2b Trial 68 Dalbavancin 68 RNAi Therapeutics 68 HGS ETR1 mapatumumab 68 Immunotherapeutic 68 CCR9 antagonist 68 Nanobody 68 trastuzumab DM1 T DM1 68 hypoxia inducible factor 68 Hsp# Inhibitor 68 mTOR mammalian target 68 Initiates Clinical Trial 68 TRX1 68 HDAC Inhibitor 68 phase IIb clinical 68 ATTR 68 Ozarelix 68 evaluating tivozanib 68 elotuzumab 68 vidofludimus 68 PLK1 SNALP 68 M2 subunit 68 novel antiviral therapeutics 68 Solazed ™ 68 Vidofludimus 68 vascular disrupting agent 68 Trofex 68 Epidermal Growth Factor Receptor 68 Kinase Inhibitor 68 ENMD # 68 histone deacetylase inhibitor 68 XOMA 3AB 68 erlotinib Tarceva ® 68 Factor Receptor 68 Tyrosine Kinase Inhibitor 68 huC# DM4 68 Initiates Enrollment 68 SinuNase ™ 68 Phase #/#a trial 68 agonistic human 68 IMA# 68 ARRY # 68 p# biomarker 68 Vaccine Adjuvant 68 GW# [003] 68 Diabetic Macular Edema DME 68 molecular imaging radiopharmaceutical 68 OHR/AVR# 68 Bezielle 68 Preclinical Data 68 PHX# 68 IMC #B 68 Azedra ™ 68 TKM ApoB 67 TRANSDUR ® 67 severe hypercholesterolemia 67 liposomal formulation 67 Janus kinase 67 highly selective inhibitor 67 Xanafide 67 Aganocide 67 PEGylated Fab fragment 67 prostate cancer antigen prostatic 67 CTAP# Capsules 67 Onalta TM 67 therapeutic monoclonal antibody 67 ELADUR ™ 67 small molecule defensin 67 Initiates Phase II 67 candidates Azedra TM 67 Elagolix 67 glucagon receptor 67 small molecule Hedgehog 67 ospemifene 67 Phase IIb Clinical Trial 67 Voreloxin 67 Factor VIIa 67 TPI ASM8 67 THR beta agonist 67 Antibody Drug Conjugate 67 selective kinase inhibitor 67 PI3K/mTOR 67 Cutaneous T 67 TRAIL receptor antibodies 67 acetonide FA 67 MTP inhibitor 67 PNT# 67 TTR amyloidosis 67 Xyfid TM 67 Daclizumab 67 systemic fungal infections 67 multi kinase inhibitor 67 DOS# 67 toenail onychomycosis 67 Hedgehog Pathway Inhibitor 67 NPC 1C 67 cutaneous T 67 MKC# MKC# PP 67 p# inhibitor 67 SAR# [004] 67 HGS# 67 2 methoxyestradiol 67 CD# monoclonal antibody 67 HCD# [002] 67 IRX 2 67 RNAi therapeutic 67 tubulin inhibitor 67 Exherin TM 67 MGd 67 diarrhea predominant irritable 67 CCR5 antagonist 67 sodium thiosulfate STS 67 OvaRex R 67 PEGylated interferon beta 1a 67 investigational monoclonal antibody 67 Iluvien ® 67 Receives Orphan Drug Designation 67 topically applied SEPA 67 acid phosphatase PAP 67 PEGylated anti 67 gastro intestinal inflammation 67 novel nucleoside analog 67 Romidepsin 67 Tesetaxel 67 Presents Preclinical 67 Diabetic Macular Edema 67 siRNA therapeutic 67 PDX pralatrexate 67 IMiDs R 67 Exelixis XL# 67 Lenocta 67 OncoVEX GM CSF 67 TTR gene 67 recombinant subunit vaccine 67 SIRT1 activators 67 POSIDUR TM ELADUR TM 67 Bavituximab 67 castrate resistant prostate cancer 67 Epratuzumab 67 obatoclax 67 ONCONASE R 67 anti botulism antibody 67 vapreotide acetate 67 Phase 2a Clinical Trial 67 Cethromycin 67 Tarvacin TM 67 INCB# [001] 67 siRNAs targeting 67 HGS ETR2 67 CD3 monoclonal antibody 67 Cloretazine ® 67 hypereosinophilic syndrome 67 Zemiva TM Trofex TM 67 CINTREDEKIN BESUDOTOX 67 sodium glucose cotransporter 67 Sudhir Agrawal D.Phil 67 IMiDs ® 67 psoriasis rheumatoid arthritis 67 Receives Orphan Drug 67 Zemiva ™ 67 Rigel R# 67 Virulizin ® 67 aldehyde dehydrogenase ALDH2 deficiency 67 Phase III Pivotal 67 humanized monoclonal 67 JAK inhibitor 67 histone deacetylase 67 OXi# 67 chemotherapy induced neutropenia 67 Myocet 67 delivers fluocinolone acetonide FA 67 Aurexis 67 mGluR2 NAM 67 Phenoptin 67 transthyretin TTR 67 romazarit 67 TACI Ig 66 YONDELIS 66 DiLA2 66 ALN HTT 66 Monoclonal Antibody 66 pharmacological chaperone 66 pan HDAC inhibitor 66 non nucleoside HCV 66 Guanilib 66 Alocrest 66 RAV# 66 NASH Huntington 66 Apoptone 66 telomerase therapeutic 66 HDL Mimetic Peptide 66 methylnaltrexone bromide 66 LEP ETU 66 apoptosis inducer 66 sorafenib tablets 66 Initiates Clinical 66 otelixizumab 66 anionic backbone 66 Vascugel 66 dihydrochloride Tablets 66 Bicifadine 66 catalytic antioxidant compounds 66 ATL# [001] 66 Metastatic Melanoma 66 XL# XL# XL# 66 FLT3 66 TRIOLEX ™ 66 acadesine 66 A3 adenosine receptor 66 P#X# antagonist 66 thiazolides 66 Liprotamase 66 NS5b 66 Reports Preclinical Data 66 stable nucleic acid 66 MCSP respectively 66 volociximab 66 Phase 2a Trial 66 NEUGENE 66 product candidate Lpathomab 66 developing Bicifadine serotonin 66 PEGPH# 66 antisense inhibitors 66 Sphingomab TM 66 accumulate preferentially 66 candidate XP# 66 Telik logo TELINTRA 66 polymerase inhibitor 66 MyVax R 66 Carfilzomib 66 NovaBay Aganocide compounds 66 product platforms AZX# 66 Phase III Clinical Trial 66 engineered RAP peptides 66 HCV Protease Inhibitor 66 Ceflatonin R 66 generation purine nucleoside 66 Radezolid 66 Severe Sepsis 66 Thiarabine 66 Protein Kinase C 66 GVAX ® 66 CCX# B 66 Tyrima 66 alpha folate receptor 66 hyperphenylalaninemia HPA due 66 allosteric modulator NAM 66 LymphoStat B TM 66 Presents Positive 66 Interferon alpha 66 Aplidin R 66 RELOVAIR ™ 66 therapeutic monoclonal antibodies 66 orally bioavailable 66 TRIOLEX HE# APOPTONE HE# 66 leading oral taxane 66 Chemokine Receptor 66 PSN# [002] 66 Phase IIb clinical trials 66 thetreatment 66 Trofex TM 66 Alvine Pharmaceuticals 66 HCV protease 66 #ME# 66 Prolongs Survival 66 Drug Candidate 66 Aflibercept 66 Small Molecule 66 vivo validation 66 Plicera 66 Hedgehog pathway inhibitor 66 potently inhibit 66 dasatinib Sprycel 66 Prodarsan R 66 RhuDex ® 66 Triapine 66 Pimavanserin 66 Pathway Inhibitor 66 EVIZON TM 66 Valortim ® 66 novel RNAi therapeutics 66 EGFR HER2 66 Panzem R NCD 66 phase IIa clinical 66 diabetic neuropathic pain 66 CYP#A# CYP#D# 66 Files Investigational 66 Granted Orphan Drug 66 Cerebril TM 66 samarium Sm 66 PROVENGE sipuleucel T 66 LHRH antagonists 66 cell lymphoma CTCL 66 Evoltra ® 66 Anticalin R 66 rusalatide acetate 66 HGS ETR1 66 ARIKACE ™ 66 platinum chemotherapeutic 66 CIMZIA TM 66 candidate deforolimus 66 ANAVEX #-# [001] 66 Ampligen ® 66 cystinosis patients 66 PROSTASCINT R 66 mapatumumab 66 Ostarine ™ 66 BiovaxID TM 66 CRLX# 66 nephropathic cystinosis 66 Phase Ib clinical trials 66 B lymphocyte stimulator 66 IMiDs 66 Soliris eculizumab 66 targeted antifolate 66 Albuferon TM 66 phase IIb study 66 PRTX 66 ALK inhibitor 66 LymphoStat B belimumab 66 lucinactant 66 CB2 selective receptor agonist 66 somatostatin analogue 66 NS#/#A protease 66 PROGENSA R 66 Epothilones 66 Inhalation Solution 66 Phase IIb Trial 66 demonstrated antitumor activity 66 oral nucleoside analogue 66 Alnylam #x# 66 SPL# Gel vaginal microbicide 66 XP# XP# 66 TLK# 66 Insegia 66 Pafuramidine 66 MAXY G# 66 monoclonal antibody MAb 66 ABL inhibitor 66 TNF Tumor Necrosis Factor 66 ZFP Therapeutic 66 docetaxel Taxotere R 66 sapropterin dihydrochloride 66 platform HDL Mimetic 66 orally inhaled migraine 65 SinuNase TM 65 pralatrexate injection folate analogue 65 mitogen activated ERK kinase 65 Initiate Phase 65 nucleotide analog 65 Combination REOLYSIN R 65 Files IND 65 XL# XL# XL# XL# 65 SARMs 65 personalized cellular immunotherapy 65 Onalta 65 Zorbtive TM 65 BCG refractory carcinoma 65 EZN 65 imatinib Gleevec ® 65 Fabry Disease 65 Curaxin CBLC# 65 oncolytic vaccine 65 telomerase inhibitor drug 65 glucokinase activator 65 adalimumab Humira 65 SNT MC# 65 lead molecular radiotherapeutic 65 Recombinant Human 65 Advanced Renal Cell 65 Vidaza ® 65 antisense inhibitor 65 Announces Poster Presentations 65 Homspera TM 65 Vascular Disrupting Agent 65 ATTR CM 65 RAS MAPK pathway 65 Pancreate 65 Valortim R 65 beta 1a 65 Phase Ib study 65 mGluR5 negative 65 BrachySil TM 65 APOPTONE 65 trastuzumab Herceptin R 65 neuro inflammatory 65 Therapeutic Vaccine 65 ocular formulation 65 Phase 1a clinical 65 TELINTRA 65 AEGR 65 Hepatitis C HCV 65 Disease IBD 65 Pivotal Phase III 65 T#I [002] 65 TRO# 65 Initiates Dosing 65 AP# [003] 65 R#/MEM 65 proprietary polysaccharide 65 hepatitis C HCV 65 Oracea TM 65 inflammatory autoimmune diseases 65 triciribine phosphate monohydrate 65 Successfully Completes Phase 65 Preclinical studies suggest 65 epigenetic therapies 65 Chronic Lymphocytic Leukemia CLL 65 Valortim TM 65 Azedra TM Onalta TM 65 Onconase 65 IMPDH inhibitor 65 tafamidis 65 Initiates Phase III 65 cetuximab Erbitux R 65 registrational 65 Curaxin 65 Otelixizumab 65 Aurora Kinase 65 Generx TM 65 Xcytrin R 65 GATTEX ™ 65 Azedra TM 65 Acute Radiation Syndrome ARS 65 Panzem 65 INS# [001] 65 Leukemias 65 immunotherapeutic agent 65 Kuvan R 65 docetaxel Taxotere ® 65 PANVAC VF 65 AzaSite Plus 65 delafloxacin 65 Chimigen TM 65 mertansine 65 humanized antibody 65 inhibitor RG# 65 Symadex 65 Solazed 65 include PLX IBD 65 T#I mutant 65 Perifosine 65 mu opioid receptor antagonist 65 Sapacitabine 65 ZOLINZA 65 Bucindolol 65 anticoagulant reversing agent 65 delta gamma agonist 65 anti amnesic 65 ON #.Na 65 registrational trial 65 investigational therapies 65 IgG1 antibody 65 Serostim ® 65 ALV# 65 novel peptides 65 Pralatrexate 65 schizophrenia CIAS 65 ketolide antibiotic 65 triggers apoptosis programmed 65 sunitinib Sutent ® 65 histone methyltransferases HMTs 65 5 HT2A inverse 65 acyclovir Lauriad R 65 TAFA# 65 ALTROPANE R 65 vinca alkaloid 65 intranasal insulin product 65 Present Preclinical Data 65 selective inhibition 65 including eniluracil ADH 65 antisense drug 65 catheter occlusion 65 Antitumor Activity 65 Sym# 65 Histone Deacetylase 65 inhaled liposomal ciprofloxacin 65 ThermoDox ® clinical 65 MEK inhibitors 65 ONX 65 KNS # 65 small molecule tyrosine 65 PKC# 65 delta isoform 65 Clusterin 65 CCR5 mAb 65 StaphVAX R 65 HIV integrase inhibitors 65 Novel Mechanism 65 BENLYSTA TM 65 CBLC# 65 immuno inflammatory diseases 65 AKT inhibitor 65 TG# [003] 65 chimeric monoclonal antibody 65 GATTEX TM 65 Synavive ™ 65 gefitinib Iressa 65 generation nucleoside analog 65 RANK Ligand inhibitor 65 Optiquel ™ 65 ZFP Therapeutics 65 DNA methyltransferase inhibitors 65 cannabinor 65 ApoB SNALP 65 Triolex 65 Mipomersen 65 R Saizen R 65 LUMINATE 65 XL# inhibits 65 Vicinium TM 65 including thyroiditis RA 65 peptidic compound 65 SAR# [002] 65 Belimumab 65 BiTE antibody 65 selective immunoproteasome inhibitor 65 OncoVEX 65 Telatinib 65 Tumour Vascular Disrupting Agent 65 Solid Tumors 65 lomitapide 65 aurora kinase 65 MT# MEDI 65 HCV NS5B polymerase 65 radezolid 65 vascular disrupting agents 65 molecular imaging radiopharmaceuticals 65 anti CD3 monoclonal 65 next generation URAT1 65 intravesical instillation 65 SNALP technology 65 Complicated Skin 65 investigational pan BCR 65 TLR antagonists 65 R roscovitine 65 dextromethorphan quinidine 65 Golimumab 65 Delafloxacin 65 CINQUIL 65 PI3K/Akt pathway inhibitor 65 dacetuzumab 65 antiangiogenesis therapies 65 2 inhibitor CYT# 65 small molecule activator 65 Cloretazine R 65 SERMs 65 refractory gout 65 TÎ ² 4 65 EGS# 65 chemically modified siRNA 65 tumor xenograft models 65 humanized monoclonal antibodies 65 OMP #M# 65 JAK2 kinase 65 Protexia ® 65 Kosan dependence 65 NABTT 65 Blinatumomab 65 IgG1 monoclonal antibody 65 GATTEX ® 65 Gleevec resistant 65 Saxagliptin 65 metastatic colorectal 65 Oral Fingolimod 65 HuCAL PLATINUM ® CysDisplay 65 HSP# inhibitor 65 Preclinical Efficacy 65 Cannabinor 65 Deforolimus 65 Epstein Barr Virus EBV 65 DermaVir Patch 65 Ecallantide 65 IMiDs ® compound 65 nucleoside analog 65 mda 7 64 small molecule thrombopoietin 64 metastatic hormone refractory 64 bevacizumab Avastin ® 64 REMOXY R 64 Enzastaurin 64 AKIP ™ 64 LNPs 64 candidates Azedra 64 pathophysiological effects 64 targeting Inflammatory Bowel 64 compound INCB# 64 Hematological Malignancies 64 Civacir 64 AeroLEF TM 64 PEG PAL 64 DCVax R 64 huN# DM1 64 signal transduction inhibitor 64 R sorafenib tablets 64 Maribavir 64 eTag assays 64 Bosutinib 64 AVONEX ® 64 evaluating picoplatin 64 Interferon Beta 64 Dendritic Cells 64 bardoxolone 64 epithelial tumors 64 ularitide 64 Nexavar ® 64 ZEVALIN ® 64 Surfaxin LS 64 GAMMAGARD 64 polysaccharide polymer 64 torezolid phosphate 64 recombinant biopharmaceutical 64 sarcoma melanoma 64 pertuzumab 64 systemic anaplastic large 64 JAK#/JAK# 64 Denufosol 64 visilizumab 64 Kuvan TM sapropterin 64 Preclinical Study 64 ELADUR TM 64 SYN# 64 Beta catenin pathway 64 RhuDex R 64 Hsp# inhibition 64 PF # [002] 64 investigational hepatitis C 64 class anticancer quinolone 64 Genasense ® oblimersen 64 monoclonal antibody conjugated 64 PREOS R 64 MEK Inhibitor 64 thymalfasin 64 RNA antagonist 64 neuro inflammatory disorders 64 Cetrorelix 64 Thiovir 64 Investigational Treatment 64 OncoVex 64 FUSILEV ® 64 Ridaforolimus 64 Pharmacokinetics PK 64 TBC# 64 favorable pharmacokinetic profile 64 Begins Dosing 64 prokinetic agent 64 Vidaza R 64 either acutely decompensated 64 ILUVIEN ® 64 Selective Electrochemical Tumor Ablation 64 compound PMX # 64 Locked Nucleic Acid 64 BRAF kinase 64 Addex Pharmaceuticals www.addexpharma.com discoverMunsif Khan spokesman 64 encapsulates siRNAs 64 COX Inhibiting Nitric Oxide 64 SuperAntibody 64 PSMA ADC 64 darinaparsin ZIO 64 Nektar proprietary 64 targeting miR 64 ELACYT 64 M# rationally 64 Initiates Phase 64 vosaroxin 64 Annamycin 64 Syncria R 64 Locked Nucleic Acid LNA 64 Marqibo TM 64 Phase 2a clinical trials 64 radiation sensitizer 64 DPX Survivac 64 Patient Enrollment 64 Fx #A 64 MyVax ® 64 Aliskiren 64 OTCQB CTIX 64 Zenvia Phase III 64 immunomodulatory therapy 64 NTDDS 64 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 64 formerly LymphoStat B 64 pan histone deacetylase 64 dual PPAR peroxisome 64 DURECT proprietary 64 Anti Tumor 64 Ph.D. Targacept 64 recurrent glioma 64 dyskinesia PD LID 64 CD# antibody [001] 64 chronic eosinophilic leukemia 64 Panzem ® 64 BCX# 64 Trodusquemine MSI 64 Pruvel TM 64 octreotide implant 64 ATL# [002] 64 leukemia AML 64 Septin9 biomarker 64 MVA BN R 64 Prednisporin 64 ulimorelin 64 PGL# 64 relapsing multiple sclerosis 64 Lenocta TM 64 pediatric Crohn disease 64 Viprovex R 64 sapropterin dihydrochloride Tablets 64 Tß4 64 Clinical Trial Results 64 humanized monoclonal antibody 64 HuMax EGFr 64 HBeAg negative 64 gastrointestinal disorders ATI 64 paclitaxel poliglumex 64 investigational antiplatelet agent 64 Alinia 64 Kamada AAT 64 monoclonal antibody IgG1 Mab 64 vinorelbine tartrate 64 PEGylated 64 Altastaph 64 oncolytic 64 Aganocide ® 64 predictive biomarkers 64 ZFP TF 64 SPRYCEL ® 64 Glufosfamide 64 Fludara ® 64 Elotuzumab 64 % uracil topical 64 Afatinib 64 TLR9 agonists 64 Investigational Drug 64 OMNARIS Nasal Spray 64 VEGF inhibitors 64 Receives Fast Track 64 Pyridorin 64 orally bioavailable mimics 64 Exelixis compounds 64 TELINTRA R 64 sodium Injection 64 velafermin 64 opioid induced constipation OIC 64 Hypoxia Inducible Factor 64 proliferator activated receptor 64 compound AEZS 64 nilotinib Tasigna ® 64 NeoLipid R 64 cetuximab Erbitux ® 64 Wafer polifeprosan 64 KRN# 64 Aviptadil 64 MGCD# [001] 64 autologous cellular immunotherapy 64 polyneuropathy HIV DSP 64 Alferon LDO 64 Virulizin R 64 Ceflatonin 64 PORxin TM 64 CRMD# 64 JAK3 64 VentiRx Pharmaceuticals 64 Diamyd ® 64 Bafetinib 64 Decitabine 64 siRNA therapeutics 64 neuropathic pain metabolic diseases 64 Intravenous Human 64 ATL/TV# 64 cathepsin K inhibitor 64 A1PI 64 cleavable linker 64 candidates bavituximab 64 tumors GIST 64 peptibody 64 TREANDA 64 QUADRAMET R 64 REMOXY ® 64 HDL Therapy 64 interleukin IL -# 64 oral picoplatin 64 poly ADP ribose polymerase 64 Tasimelteon 64 Universal Flu Vaccine 64 AQ4N 64 Phase Ib Clinical Trial 64 Microplasmin 64 Ofatumumab 64 GSK# [001] 64 Anti CD# Antibody 64 Potelligent Technology 64 eniluracil 64 Aurora kinase 64 vaccine GRNVAC1 64 metastatic castration resistant 64 AFREZZA TM 64 isoform selective 64 rheumatoid arthritis thrombocytopenia 64 Celgosivir 64 ADP receptor antagonist 64 occlusion PAO 64 VEGFR2 inhibitor 64 Nanobodies 64 Panzem NCD 64 CRTH2 64 Aurexis R 64 HTS assay 64 Zolinza 64 Aryplase 64 superficial bladder cancer 64 essential thrombocythemia 64 tezampanel 64 Pivotal Phase 64 patented Bioral 64 chemokine receptor 64 Dasatinib 64 immunotherapeutic approaches 64 HER2 ErbB2 64 proteasome inhibitors 64 ONCONASE 64 novel therapeutic antibodies 64 Epothilone D 64 equine osteoarthritis 64 #I TM# 64 Achieves Primary Endpoint 64 small molecule agonists 64 Randomized Phase 64 myelofibrosis MF 64 5 HT6 64 Oral NKTR 64 adecatumumab MT# 64 Ophena TM 64 Neutrolin ® 64 Phase 2a trial 64 optimal dosing regimens 64 Novel Inhibitor 64 non nucleoside 64 XmAb# 64 5 HT3 antagonist 64 XYOTAX TM 64 Viprovex TM 64 anti infective treatments 64 HuMax TAC 64 Aptamer 64 P#X# 64 Kit CD# positive 64 Sphingomab 64 Atiprimod 64 drug pipeline TAFA# 64 intranasal formulation 64 investigational immunotherapy 64 polycythemia vera PV 64 BCR ABL inhibitor 64 SUTENT ® 64 Quinamed 64 ZADAXIN ® 64 Xeloda ® 64 Veronate R 64 Maxy G# 64 virus HCV infection 64 Cyclooxygenase Inhibiting Nitric Oxide 64 anti CD3 64 oral ghrelin agonist 64 lymphoid malignancies 64 Luteinizing Hormone Releasing Hormone 64 FGFR 64 herpetic keratitis 64 human IgG1 monoclonal 64 Initiates Phase 2b 64 Vitrasert R 64 DB# [003] 64 Campath alemtuzumab 64 Adnectin 64 histone deacetylase HDAC 64 metastatic neuroendocrine tumors 64 VitiGam TM 64 Alzhemed TM 64 Stapled Peptide 64 Alferon N